SKVI — Skinvisible Share Price
Last trade - 00:00- $0.46m
- $6.61m
- $0.02m
- 27
- 15
- 45
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 22.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -2451.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.04 | 0.28 | 0.66 | 0.28 | 0.02 | n/a | n/a | -22.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 5th, 1998
- Public Since
- January 7th, 1999
- No. of Employees
- 2
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,539,843
- Address
- 6320 S SANDHILL ROAD, UNIT 9, LAS VEGAS, 89120
- Web
- http://www.skinvisible.com/
- Phone
- +1 7024337154
- Auditors
- Gries & Associates, LLC
Upcoming Events for SKVI
Similar to SKVI
American Education Center
Pink Sheets on Nasdaq
Arem Pacific
Pink Sheets on Nasdaq
Axia International
Pink Sheets on Nasdaq
Ascendia Brands
Pink Sheets on Nasdaq
Aspen
Pink Sheets on Nasdaq
FAQ
As of Today at 19:19 UTC, shares in Skinvisible are trading at $0.10. This share price information is delayed by 15 minutes.
Shares in Skinvisible last closed at $0.10 and the price had moved by -0.88% over the past 365 days. In terms of relative price strength the Skinvisible share price has underperformed the S&P500 Index by -12.55% over the past year.
There is no consensus recommendation for this security.
Skinvisible does not currently pay a dividend.
Skinvisible does not currently pay a dividend.
Skinvisible does not currently pay a dividend.
To buy shares in Skinvisible you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.10, shares in Skinvisible had a market capitalisation of $0.46m.
Here are the trading details for Skinvisible:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SKVI
Based on an overall assessment of its quality, value and momentum Skinvisible is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Skinvisible. Over the past six months, its share price has outperformed the S&P500 Index by +45.12%.
As of the last closing price of $0.10, shares in Skinvisible were trading -18.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Skinvisible PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Skinvisible's management team is headed by:
- Terry Howlett - CEO
- Greg McCartney - DRC
- David St. James - DRC